Deleted Tweets From Scott Gottlieb, R-D.C.

RT @Surgeon_General: Up at the White Oak @US_FDA campus this afternoon to be briefed by @FDATobacco & got to say hi to my colleague and… https://t.co/a913Er4UuE

#FDA sent 904B letters to manufacturers of some e-cig products requesting certain information to better understand why these products may be appealing to kids. We'll follow up on these actions and will take other steps to target youth access to e-cigs htt

Depending on what we learn, based on the information we requested, #FDA can take a range of actions to address violations that might be fueling the youth use. We can also inspect facilities, and review records, if we believe they haven't responded to our

RT @FDATobacco: FDA is seeking scientific evidence related to the role that flavors, including menthol, play in tobacco product use… https://t.co/EfUZRG94Z5

RT @alliancerm: We're excited to see everyone tomorrow! Don't miss our policy briefing with @US_FDA Commissioner @SGottliebFDA & ou… https://t.co/r7VP3u7AXV

RT @FDAJobs: Happy Monday twitter family! Want to know where FDA Recruitment will be next? Check out our list of upcoming confer… https://t.co/64PMcw5t5t

RT @FDA_ORA: #FDAORA is hiring! Current FDA employees can apply to become a part of the Bioresearch Monitoring Program (BIMO) fo… https://t.co/GBUfx6HoLN

FDA is seeking scientific evidence related to the role that flavors, including menthol, play in tobacco product use. Share your input on how to best regulate flavors in tobacco products through June 19. https://t.co/ITePitnisl

#FDA is pleased to be supporting @SecAzar trip to the @WHO World Health Assembly, where among the topics he’s discussing with world health leaders is the #HHS and FDA’s & CDC’s response to the #Ebola outbreak in the #DRC #WHA71 @HHS @US_FDA https://t.

RT @FDATobacco: Exposure to the nicotine in e-liquids can be toxic, especially to young children. Severe harms can occur if the e-l… https://t.co/C9kdB3WwLj

When the House passes #RightToTry legislation I stand ready to implement it in a way that achieves Congress’ intent to promote access and protect patients; and build on #FDA’s longstanding commitment to these important goals #RTT

RT @FDAOncology: FDA Commissioner @SGottliebFDA to address #ASCO18 on Saturday, June 2, Plenary Session in Hall B1, McCormick Center https://t.co/10cJyGqo2b

RT @FDAMedia: Statement from @SGottliebFDA on new FDA actions to keep consumers safe from the harmful effects of sun exposure, an… https://t.co/1jj5O6LVZW

We’ll soon release a framework similar to the Regenerative Medicine framework that’ll explain how we intend to address manufacturing issues and the development pathway for gene therapy products https://t.co/XVqmRtqUrC

Among the guidance documents we’ll unveil as part of our comprehensive policy framework are documents that’ll lay out potential accelerated approval endpoints for certain gene therapy products.

FDA has more than 500 active investigational new drug applications involving gene therapy products. We’ve received more than 100 such applications last year alone. This shows the intensity of scientific work going on in this field.

From Dec 2016 – April 2018 there were 62 RMAT designation submissions. 19 of those were granted with 14 also having an orphan designation. This shows how program is promoting development in the rare disease space. #RegenMed

RT @US_FDA: The FDA is issuing draft guidance to industry to provide manufacturers with recommendations about how to study the… https://t.co/frBXgbw0t1

The first therapeutic area we’ll focus on is hemophilia, where factor production may be sufficient in some cases as a surrogate measure of benefit where a gene therapy product can potentially normalize factor production.

Today we sent warning letters to five companies illegally marketing pills and capsules labeled as dietary supplements that made unproven drug claims about protecting consumers from sun exposure. https://t.co/RvJCyfNYI2 https://t.co/t5KTKww4UI

RT @Surgeon_General: Up at the White Oak @US_FDA campus this afternoon to be briefed by @FDATobacco & got to say hi to my colleague and… https://t.co/a913Er4UuE

#FDA sent 904B letters to manufacturers of some e-cig products requesting certain information to better understand why these products may be appealing to kids. We'll follow up on these actions and will take other steps to target youth access to e-cigs htt

Depending on what we learn, based on the information we requested, #FDA can take a range of actions to address violations that might be fueling the youth use. We can also inspect facilities, and review records, if we believe they haven't responded to our

RT @FDATobacco: FDA is seeking scientific evidence related to the role that flavors, including menthol, play in tobacco product use… https://t.co/EfUZRG94Z5

RT @alliancerm: We're excited to see everyone tomorrow! Don't miss our policy briefing with @US_FDA Commissioner @SGottliebFDA & ou… https://t.co/r7VP3u7AXV

RT @FDAJobs: Happy Monday twitter family! Want to know where FDA Recruitment will be next? Check out our list of upcoming confer… https://t.co/64PMcw5t5t

RT @FDA_ORA: #FDAORA is hiring! Current FDA employees can apply to become a part of the Bioresearch Monitoring Program (BIMO) fo… https://t.co/GBUfx6HoLN

FDA is seeking scientific evidence related to the role that flavors, including menthol, play in tobacco product use. Share your input on how to best regulate flavors in tobacco products through June 19. https://t.co/ITePitnisl

#FDA is pleased to be supporting @SecAzar trip to the @WHO World Health Assembly, where among the topics he’s discussing with world health leaders is the #HHS and FDA’s & CDC’s response to the #Ebola outbreak in the #DRC #WHA71 @HHS @US_FDA https://t.

RT @FDATobacco: Exposure to the nicotine in e-liquids can be toxic, especially to young children. Severe harms can occur if the e-l… https://t.co/C9kdB3WwLj

When the House passes #RightToTry legislation I stand ready to implement it in a way that achieves Congress’ intent to promote access and protect patients; and build on #FDA’s longstanding commitment to these important goals #RTT

RT @FDAOncology: FDA Commissioner @SGottliebFDA to address #ASCO18 on Saturday, June 2, Plenary Session in Hall B1, McCormick Center https://t.co/10cJyGqo2b

RT @FDAMedia: Statement from @SGottliebFDA on new FDA actions to keep consumers safe from the harmful effects of sun exposure, an… https://t.co/1jj5O6LVZW

We’ll soon release a framework similar to the Regenerative Medicine framework that’ll explain how we intend to address manufacturing issues and the development pathway for gene therapy products https://t.co/XVqmRtqUrC

Among the guidance documents we’ll unveil as part of our comprehensive policy framework are documents that’ll lay out potential accelerated approval endpoints for certain gene therapy products.

FDA has more than 500 active investigational new drug applications involving gene therapy products. We’ve received more than 100 such applications last year alone. This shows the intensity of scientific work going on in this field.

From Dec 2016 – April 2018 there were 62 RMAT designation submissions. 19 of those were granted with 14 also having an orphan designation. This shows how program is promoting development in the rare disease space. #RegenMed

RT @US_FDA: The FDA is issuing draft guidance to industry to provide manufacturers with recommendations about how to study the… https://t.co/frBXgbw0t1

The first therapeutic area we’ll focus on is hemophilia, where factor production may be sufficient in some cases as a surrogate measure of benefit where a gene therapy product can potentially normalize factor production.

Today we sent warning letters to five companies illegally marketing pills and capsules labeled as dietary supplements that made unproven drug claims about protecting consumers from sun exposure. https://t.co/RvJCyfNYI2 https://t.co/t5KTKww4UI